Article
Tumor mutational burden is associated with poor outcomes in diffuse glioma.
BMC cancer - 12 Mar 2020
Wang Lihong, Ge Jia, Lan Yang, Shi Yu, Luo Ying, Tan Yuhuan, Liang Mei, Deng Song, Zhang Xia, Wang Wenying, Tan Yaoyao, Xu Yuanyuan, Luo Tao
Abstract excerpt
BACKGROUND: Tumor mutational burden (TMB) is a potential biomarker for immune checkpoint therapy and prognosis. The impact of TMB on clinical outcomes and the correlation coefficient between exome sequencing and targeted sequencing in glioma have not yet been explored. METHODS: Somatic mutations in the coding regions of 897 primary gliomas and the clinical and RNA-seq data of 654 patients in The Cancer Genome...
Topics
Join the communities discussing this publication.